Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Volatility & Risk
Ernexa Therapeutics has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.
Valuation & Earnings
This table compares Ernexa Therapeutics and Autolus Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 8.32 | -$14.08 million | ($14.35) | -0.21 |
| Autolus Therapeutics | $117.39 million | 4.04 | -$287.53 million | ($1.06) | -1.68 |
Ernexa Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Ernexa Therapeutics and Autolus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Ernexa Therapeutics and Autolus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 913.51%. Autolus Therapeutics has a consensus target price of $10.00, indicating a potential upside of 461.80%. Given Ernexa Therapeutics’ higher probable upside, equities research analysts plainly believe Ernexa Therapeutics is more favorable than Autolus Therapeutics.
Summary
Autolus Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
